Sarepta Therapeutics (SRPT) says adverse event report was erroneously submitted to FDA's FAERs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta Therapeutics (SRPT) to Resume Trading at 3:45 pm
August 8, 2019 3:34 PM EDTSarepta Therapeutics (NASDAQ: SRPT) to Resume Trading at 3:45 pm
... MoreSarepta Therapeutics (SRPT) option implied volatility at 55, call put ratio 1.6 calls to 1 put into trading halt
August 8, 2019 2:23 PM EDTSarepta Therapeutics (NASDAQ: SRPT) 30 day call option implied volatility is at 55 compared to its 52-week range of 48 to 87 into trading halt.
... MoreSarepta Therapeutics (SRPT) Weakness Should Be Bought - Nomura/Instinet
August 8, 2019 2:02 PM EDTNomura/Instinet analyst Christopher Marai reiterated a Buy rating and $230.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) with shares halted at noon pending news of an SAE potentially related to SRP-9001, made public on the FDA FAERs database; the SAE was disclosed to be due to rhabdomyolysis.
Marai commented, "The FAERs database... More
FDA Adverse Event May Not Be 'Major Showstopper' for Sarepta Therapeutics (SRPT) Program - RBC
August 8, 2019 1:08 PM EDTRBC Capital analyst Brian Abrahams weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the FDA's adverse events database cited a case of rhabdomyolysis leading to hospitalization in a patient who had received their microdystrophin gene therapy.
The analyst notes several reasons it may not be a major showstopper for the program:
1) The event occurred back in early February, and the trial continued with rapid enrollment for months thereafter,... More
Sarepta Therapeutics (SRPT) Halted, News Pending
August 8, 2019 12:29 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Halted, News Pending
Sarepta Therapeutics (SRPT) Resumes Trading
August 8, 2019 12:20 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Resumes Trading
... MoreSarepta Therapeutics (SRPT) Halted on LUDP
August 8, 2019 12:15 PM EDTSarepta Therapeutics (NASDAQ: SRPT) Halted on LUDP
Sarepta (SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
August 8, 2019 12:10 PM EDTSarepta's (NASDAQ: SRPT) SRP-9001 Safety Issue Appears in FDA's FAERS System - Bloomberg
